Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × eprenetapopt × Clear all
NCT03072043 2022-01-24

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
55 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡